Margaret H. Veldman-Jones

Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth

Jin Gao, Jon Chesebrough, Susan A. Cartlidge et al. · Cancer Research · 2011 · 119 citations

Insulin-like Growth Factors, Tumor Growth, Medicine +14

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib

Michael G. Rolf, Jon Curwen, Margaret H. Veldman-Jones et al. · Pharmacology Research & Perspectives · 2015 · 108 citations · Full text

Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System

Margaret H. Veldman-Jones, Zhongwu Lai, Mark Wappett et al. · Clinical Cancer Research · 2014 · 75 citations

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Edmund Poon, Stefanie Mullins, Amanda Watkins et al. · Journal for ImmunoTherapy of Cancer · 2017 · 73 citations · Full text

Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress

Lucy A. Young, Lenka Oplustil O'Connor, Christelle de Renty et al. · Cancer Research · 2019 · 69 citations · Full text